Table 2.
Effect of the re-immunization on VEGF-specific IgG, IgA and IgM antibodies or VEGF/VEGFR2 blockade
| Patient code | IgG antibody titer | IgA antibody titer | IgM antibody titer | VEGF/VEGFR2 blockade (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-vaccination | Re-immunization phase | Pre-vaccination | Re-immunization phase | Pre-vaccination | Re-immunization phase | Pre-vaccination | Re-immunization phase | |||||
| Week 0 |
Sample A | Sample B | Week 0 |
Sample A | Sample B | Week 0 |
Sample A | Sample B |
Week 0 |
Sample A | Sample B | |
| CH08 | 4 | 36 | 31 | 49 | 70 | 71 | 1183 | 1035 | 1101 | 11.2 | 18.7 | 11.9 |
| JL12 | 26 | 700* | 770* | 49 | 93 | 56 | 298 | 528 | 604* | 6.92 | 7.5 | 15.2* |
| CQ13 | 4 | 505* | 582* | 335 | 286 | 305 | 1655 | 2090 | 2198† | 10.8 | 29.4* | 24.5* |
| CH19 | 4 | 232* | 244* | 49 | 59 | 68 | 1180 | 1462 | 1978† | 11.5 | 16.1 | 31.5*,# |
| CH20 | 1 | 374* | 339* | 110 | 94 | 62 | 963 | 629 | 675 | 4.6 | 12.1* | 16.7* |
| CH27 | 8 | 207* | 236* | 268 | 472 | 319 | 1947 | 3422 | 3732† | 14.2 | 31.1* | 29.9* |
| JL29 | 118 | 589* | 795*,† | 87 | 124 | 144 | 707 | 438 | 557† | 11.2 | 7.2 | 20.8# |
| JL30 | 1 | 17 | 17 | 69 | 72 | 75 | 886 | 663 | 688 | 14 | 19 | 18 |
| CH33 | 133 | 1655* | 1697* | 111 | 676* | 530* | 2591 | 341140* | 3859811*,† | 8.7 | 27.2* | 28.9* |
| JL42 | 41 | 40 | 56 | 70 | 73 | 96 | 1788 | 1374 | 2426† | 20 | 17 | 27# |
| CH45 | 0 | 4474* | 3825* | 48 | 80 | 84 | 543 | 4108* | 4995*,† | 7.6 | 27.4* | 23* |
| JL49 | 463 | 947* | 1110*,† | 70 | 155* | 125 | 509 | 1114* | 1027* | 16.3 | 27.5 | 34.1* |
Sample “A”: is the value for the sample taken just before the re-immunization; Sample “B”: is the value for the sample acquired 7–10 days after the taking of the sample “A”. [*]: sample meets the positivity criteria for specific-IgG (using formulas A and B), IgA or IgM antibodies (using formula A) or VEGF/VEGFR2 blockade (using formula D). (†): sample meets the criterion of increase for antibody titer: sample “B” - sample “A” ≥ 1/100. (#): sample meets the criterion of increase for VEGF/VEGFR2 blockade: sample “B” - sample “A” ≥ 10%. Patients: CH08 (sample A taken at week 55; sample B taken at week 56); JL12 (sample A taken at week 53; sample B taken at week 54); CQ13 (sample A taken at week 48; sample B taken at week 49); CH19 (sample A taken at week 47; sample B taken at week 48); CH20 (sample A taken at week 50; sample B taken at week 51); CH27 (sample A taken at week 45; sample B taken at week 46); JL29 (sample A taken at week 48; sample B taken at week 49); JL30 (sample A taken at week 52; sample B taken at week 53); CH33 (sample A taken at week 48; sample B taken at week 49); JL42 (sample A taken at week 49; sample B taken at week 50); CH45 (sample A taken at week 48; sample B taken at week 49); JL49 (sample A taken at week 44; sample B taken at week 45)